PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
Huaqiang Zhou, Jiaqing Liu, Yaxiong Zhang, Yan Huang, Jiayi Shen, Yunpeng Yang, Wenfeng Fang, Li Zhang
Abstract
Abstract Polybromo-1 ( PBRM1 ) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its correlation with preliminary response to immunotherapy in non-small cell lung cancer (NSCLC). Our results indicated that PBRM1 mutation was more likely to be a negative predictive biomarker for immunotherapy in NSCLC.
Topics & Concepts
ImmunotherapyMedicineBiomarkerLung cancerMutationBlockadeOncologyImmune checkpointCancer researchImmune systemRenal cell carcinomaCancerInternal medicineImmunologyGeneBiologyGeneticsReceptorCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology Studies